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Human embryonic stem cell research has elicited powerful debates about the morality of destroying human
embryos. However, there are important ethical issues related to stem cell research that are unrelated to
embryo destruction. These include particular issues involving different types of cells used, the procurement
of such cells, in vivo use of stem cells, intellectual property, and conflicts of interest.Research with human embryonic stem
cells has been inextricably associated
with ethical, social, and political debates
across the globe. Although some of these
debates relate to the integrity of research,
arguably the most vociferous and strident
debates have involved moral questions
regarding the destruction of human em-
bryos to derive stem cells. Amidst this
continuing controversy, recent reports
by different teams of scientists regarding
the possibility of reprogramming cells to
create induced pluripotent stem cells
(iPSCs) (Holden and Vogel, 2008) have
captured the imaginations of scientists
and society. Although some accounts in
the popular media suggest that the ethical
issues associated with stem cell research
will be resolved based on these results,
because their derivation does not involve
destroying embryos, such suggestions
neglect scientific arguments for continu-
ing stem cell research with embryos. Set-
ting aside for a moment the particular
issues related to research and iPSCs,
the recent reports and discussion sur-
rounding them make it at least plausible
to imagine a day when there isn’t a com-
pelling scientific call to create stem cells
from human embryos. If and when that
occurs, will all the relevant ethical debates
and considerations regarding research
and treatment with stem cells be re-
solved? Unfortunately, they will not. In fact,
there is a set of more subtle, yet serious,
ethical concerns that are embedded in
stem cell research. Accordingly, in this
paper, I describe some of the ethical
issues that are relevant to stem cell re-
search and treatment that are not related
to concerns about the embryo. It is impor-tant to acknowledge that, although many
of these issues have been raised else-
where, previous discussions have tended
to deal with them in isolation. My hope is
that by highlighting the range and nature
of these issues, those engaged in stem
cell research and its oversight may be
better prepared to examine and navigate
them in the context of basic and transla-
tional research. Such an approach should
enhance the likelihood that some of the
promises of stem cell research will be
realized into safe and effective therapies.
I also encourage individuals engaged in
stem cell research to continue to develop
and adhere to ethical guidelines that re-
flect the nature of this rapidlymoving field.
Types of Cells
There are particular considerations de-
pending on the types of cells collected
and used for stem cell research and treat-
ment, including umbilical cord blood,
bone marrow, and other somatic cells.
Many of these considerations have been
described in different literatures, but
reviewing them in aggregate suggests
some crosscutting concerns regarding
the use of human tissue for stem cell
research. Further, awareness of the con-
cerns and how they have been managed
with respect to particular cell types may
provide useful lessons and analogies for
other cell types.
Umbilical Cord Blood
An assumption by some involved with
cord blood collection is that the placenta
would be considered waste save for the
use of placental and cord blood. Although
this may be true for a majority of persons
in some parts of the globe, this may notCell Stembe true in others (Jenkins and Sugarman,
2005). Indeed, there are wide variety of
beliefs and practices regarding the proper
treatment and disposition of the placenta
that can have profound implications for
those being asked to have cord blood col-
lected. For example, in some cultures, the
placenta may be ingested by the mother
after delivery or it may be used in a variety
of ceremonial practices that can include
burial or desiccation. In addition to such
cultural concerns, there are additional
implications for pregnant women and do-
nors (Kurtzberg et al., 2005). First are a set
of questions regarding the appropriate
timing of consent. Obviously, labor and
delivery are not ideal times for delibera-
tion and careful decision making! Ideally
then, parents would provide consent for
collection in advance of labor and deliv-
ery. However, this may not be feasible
due to when and where some women
access prenatal care. In some cord blood
banking centers, clinicians obtain ‘‘mini-
consent’’ solely for the collection of cord
blood at the time of delivery. Then, subse-
quent consent is obtained for testing and
banking. Second, if cord blood will be
banked for potential use, it is typically
necessary to quarantine collected units
to ensure that they are free from transmis-
sible disease, such as HIV and hepatitis,
so that they do not cause harm to recipi-
ents. Nevertheless, the testing of a new-
born’s blood for transmissible diseases
may create unanticipated and inadvertent
harms related to privacy. Similarly, sup-
pose researchers tested banked cord
blood for adult onset disorders. What
should be done with the results of such
testing? Should parents have access toCell 2, June 2008 ª2008 Elsevier Inc. 529
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done in childhood to avert the onset of
the disorder later in life? Would parents
somehow treat differently the child with
such a result? Third, many parents have
the option of either private cord blood
banking, in which cord blood is stored
for use in their families and at their exp-
ense, and public banking, in which cord
blood is donated and stored as a public
resource at no cost to the parents. Con-
cerns that have been raised about private
banking include whether it is acceptable
to market banking services if it is currently
unlikely that the material will be used,
whether marketing of units of cord blood
is acceptable, and the disposition of
cord blood should storage fees go un-
paid.
Bone Marrow
The harvesting of bone marrow poses
obvious pain and risks to the donor. Risks
include those related to anesthesia and
physical damage coincident to harvest-
ing. Further, a range of cases have been
encountered involving the harvesting of
bone marrow for use in transplantation
that raises important ethical questions.
For example, consider the relative who
is asked to donate but doesn’t feel com-
fortable doing so or who knows about
some medical contraindication to dona-
tion (such as being HIV positive) that she
does not wish to share with her family.
Although such a person would not be
eligible to be a donor, how this private
information is handled can be difficult for
the person believed to be a potential
donor as well as for clinicians. Consider
also the now famous Ayala case, in which
a child was conceived with the hope that
she would be a suitable donor for her
sibling who stood to benefit from a bone
marrow transplant. Ultimately, she was
and a transplant was successful (Boyle
and Savulescu, 2001). However, this
case and those similar to it raise important
issues related to the appropriate use of
sibling donors who are children. Further-
more, the systems used to identify bone
marrow donors are associated with a set
of issues related to justice or fairness,
especially in regard to the ability to pro-
vide suitable donors for patients who are
members of racial and ethnic minority
communities.
Other Somatic Cells
The collection of other somatic cells (such
as adipocytes, hepatocytes, and skin530 Cell Stem Cell 2, June 2008 ª2008 Elsecells) from adults raises some discrete
but, at least to date, manageable issues.
To be sure the collection of adipocytes
and hepatocytes incurs certain discom-
fort and some discernable physical risk;
yet most adults should be capable of pro-
viding meaningful informed consent for
such collections. Nevertheless, informed
consent for such collections, as well as
the collection of skin cells by means of a
punch biopsy intended for use in develop-
ing iPSCs for research, needs to ensure
that patients who are asked to provide
specimens for the creation of stem cell
lines not harbor unrealistic expectations
regarding the likelihood that a cell line
will certainly be produced and, if so, that
it will ultimately redound in personal
benefit to them (Hyun, 2008). In addition,
when there is intent to create iPSCs, using
as an analogy the accepted provisions
that have emerged regarding the use of
human embryos to create stem cells
(Committee on Guidelines for Embryonic
Stem Cell Research, National Research
Council, 2005; Human Embryonic Stem
Cell Research Advisory Committee,
National Research Council, 2007; see
also the International Society for Stem
Cell Research [ISSCR] guidelines), it is
essential that the informed consent pro-
cess include similar information. For
example, donors must understand that
their cells may be used to create immor-
talized cell lines with future uses that
may be unclear and include the possibility
of in vivo experimentation, genetic manip-
ulation, transfer to other institutions, and
commercial potential. The lingering con-
cerns of the family members of the person
from whom the HeLa cell line was created
underscores this point (Gold, 1986;
Washington, 1994). In addition, once cell
lines have been created, it may be impos-
sible for donors to meaningfully withdraw
consent for use. Further, the extent to
which identifiable information about the
donor will be maintained should be clari-
fied.
Additionally, it appears that it is far eas-
ier to derive iPSCs than to develop hESC
lines, given in part to that fact that obtain-
ing the necessary cellular materials does
not require access to human embryos or
oocytes. Although this may prove to be
beneficial because easier derivation may
make diversity and relative scarcity of
stem cells less of an issue, concerns
have been raised about their ready usevier Inc.for types of science that raise additional
sets of ethical questions (Cyranoski,
2008). For instance, such cells may be
used in an effort to derive embryonic
germ cells with a hope of ultimately using
gametes derived from them for the treat-
ment of infertility. As part of this endeavor,
attempts would likely be made to create
embryos in the research and treatment
process, again raising ethical questions
about the embryo. Of course, these ques-
tions could arise with other types of stem
cells from different sources, provided it is
technically possible to derive germ cells
from them, but the ready availability of
skin cells from those with infertility may
make the iPSC approach seem advanta-
geous.
Procurement
Given that informed consent is now
expected for most medical research and
treatment, it is not surprising that informed
consent would be expected for procuring
cells used for stemcell research and treat-
ment (see ISSCR guidelines). Regardless
of the setting, at a very basic level in-
formed consent requires that the person
being asked to provide this consent be
capable of engaging in the consent pro-
cess, both in terms of their decision-mak-
ing capacity and ability to make a volun-
tary decision. If so, they must be given
relevant information about what is being
asked in a manner in which they can un-
derstand it. So, as described earlier, labor
and delivery can potentially compromise
the ability to provide informed consent
due to decision-making capacity at that
time, or being a graduate student or lab
worker may undermine the ability to
make a voluntary choice. It is beyond the
scope of this paper to outline all the rele-
vant information to be disclosed during
the informed consent process for each
type of procurement. However, in addition
to information regarding the procedures
for procurement and the associated risks
(physical and social), issues related to
future uses, intellectual property, owner-
ship, and control over cell lines and their
derivatives should be incorporated into
the consent process.
Privacy is another crosscutting issue
coupled to cell procurement because it
is generally important to keep identifiers
when there is a hope to use the cells
or their derivatives in clinical settings.
After all, there are legitimate concerns
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for those who provide cells. For example,
data that might be disclosed include
information about current illnesses, ge-
netic predispositions to future diseases,
and the like, which may pose social or
economic risks to the individual. Accord-
ingly, where possible, protections of
privacy should be incorporated into the
procurement process.
Finally, selecting the sources for stem
cell procurement may ultimately redound
into questions of justice. For example, if
stem cell lines are developed only among
those of a certain ethnic background, and
those lines are the ones banked and used
to develop cell-based interventions, it is
conceivable that the lines might only be
suitable for use in those of a similar back-
ground. As a result, such therapies may
not be available to those of other ethnic
groups (Bok et al., 2004). Despite the
relative ease of creating iPSCs compared
to deriving stem cell lines from embryos,
at this point it seems premature to con-
clude that it will be a simple matter to cre-
ate autologous iPSCs for transplantation
or regenerative medicine (assuming of
course that at some point they are dem-
onstrated to be safe and effective for
doing so) in such a way that will resolve
matters of justice. This is due in large
part to the current inefficiencies in the pro-
cess that translate into substantial cost,
making personal iPSCs unaffordable to
many who might stand to benefit from
a future cellular intervention (Cyranoski,
2008). In addition, depending on the pro-
posed intervention, there may be a sub-
stantial time lag between the creation of
a cell line and its availability for regenera-
tive purposes. This limitation also adds to
the likelihood that individualized iPSC
therapies will be largely impractical for
widespread clinical use.
In Vivo Use
The in vivo use of stem cells or their deriv-
atives, whether during experimentation
with nonhuman animals or humans or by
using untested interventions in an attempt
to treat patients, can each raise ethical
questions, regardless of the cell source.
Nonhuman Animals
In addition to the ethical issues associ-
ated with research involving nonhuman
animals in general, particular attention in
stem cell research has focused on the
creation of chimeras. Although chimerasdon’t seem to raise substantial ethical
issues in some settings, for example in
allogeneic bone marrow transplantation,
the creation of nonhuman-human chi-
meras has animated popular concern. Of
special relevance are studies involving
the use of neural stem cells and the possi-
bility of creating human-like characteris-
tics in primates. Taken to an extreme is
Michael Crichton’s fictionalized account
of chimeras in the novel Next. Despite
the implausibility of Crichton’s account,
it presents a set of serious issues that
are relevant to this sort of science. For ex-
ample, will the engraftment of stem cells
into the brains of nonhuman primates alter
the mental capacity of the recipient?
As such, it is essential that these sorts
of experiments receive close scrutiny
(Greene et al., 2005).
First-in-Human Use
First-in-human experiments with cell-
based interventions also raise important
ethical questions. These include obliga-
tions to have adequate preclinical evi-
dence regarding the safety of proposed
interventions, that there be reasonable
plausibility about benefit, that the scien-
tific design of the first human trials be
sound, and that there be robust attention
to obtaining meaningful informed consent
(Sugarman, 1999). It is arguably only acc-
eptable to move to a first-in-human trial
with a cell-based intervention if there is
scientific agreement about safety. Deter-
mining safetymay be particularly complex
for stem cell research (Scott, 2008). In
addition, early findings regarding iPSCs,
although exciting, still face a set of obsta-
cles that must be overcome prior to their
possible use in treating human disease.
In particular, based upon how they are
currently generated, there are concerns
about the use of viruses to transmit the re-
programming factors, their undetermined
developmental potential after transplan-
tation, and the possibility of tumor forma-
tion (Cyranoski, 2008; Holden and Vogel,
2008; Hyun, 2008; Kuehn, 2008). To the
extent possible, these sorts of issues
need to be resolved in preclinical testing
before assessing them again during
first-in-human trials.
Once such scientific questions about
safety have been addressed, focus must
shift toward assessing the likelihood that
patients will benefit at some point in the
future, even before first-in-human trials
are conducted to assess the safety ofCell Stemthis approach. That is, future benefit
should be plausible based on such factors
as determining the mechanisms of dis-
ease and the characteristics of the pro-
posed cell-based intervention. This is
especially important when the interven-
tion will pose certain harms with unknown
benefits, for instance when ablative regi-
mens are used to prevent the rejection
of a cell-based intervention.
If there is ample suggestion for the
possibility of benefit, at least to the level
of ‘‘clinical equipoise,’’ meaning that a
community of relevant experts is at least
divided about the potential for improve-
ment, the next step is the careful design
of a particular trial. Essential points for
consideration include such issues as
dose, route of administration, whether ab-
lative regimens will be employed, choice
of monitoring procedures, and the selec-
tion of appropriate outcome measures.
In addition to these issues, the selection
of particular subjects to participate in
first-in-human trials also raises important
ethical questions. For example, how
should the extent of illness affect the ap-
propriateness of participation? Although
those who are sickest may have the least
to lose, the scientific usefulness of the re-
sults of first-in-human trials might be
compromised if such patients have a
range of comorbidities that confound the
results. Alternatively, if healthier patients
participate, and the cell-based interven-
tion proves to be harmful, the subjects
may have shortened their lives or incurred
additional morbidity as a result of partici-
pating.
Further, given the hype that can be
associated with exciting emerging tech-
nologies, especially if they provide hope
for treating an otherwise untreatable con-
dition, it can be particularly difficult to
obtain consent. In short, the combination
of hype and desperation may make it dif-
ficult to convey that first-in-human trials
are conducted primarily to assess safety,
not efficacy. As efforts are taken to trans-
late research findings into clinical prac-
tice, it seems prudent to use appropriate
terms to describe the state of the field
when seeking funding, describing results,
and obtaining consent. For instance, at
this point a term such as ‘‘cell–based
intervention’’ rather than ‘‘cell-based ther-
apy’’ would be more precise because we
lack information to substantiate a claim
that these interventions will indeed beCell 2, June 2008 ª2008 Elsevier Inc. 531
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tered in describing ‘‘gene-transfer re-
search’’ as ‘‘gene therapy’’ (King, 1999).
Using Untested Cell-Based
Interventions
Complicating the usual process of care-
fully staged clinical trials has been the
availability of so-called ‘‘stem cell thera-
pies’’ in different parts of the world, prior
to rigorous demonstrations of safety and
efficacy (see report by C. Bodeen and A.
Zagier). Such programs are rarely only
local and may also attract ‘‘stem cell
tourists’’ who travel across international
borders to receive these untested inter-
ventions. Whether iPSCs will be associ-
ated with an upswing in these practices
due to their relative ease of derivation in
comparison to stem cells from embryos
(but far more complicated than using
cord blood or bone marrow) is unclear.
However, transplantation of iPSCs may
be especially treacherous, given their pro-
pensity to give rise to tumors in animal
models. Regardless, the use of cell-based
interventions of any type may violate clini-
cians’ fiduciary responsibilities to patients
because of the distinct possibility of
harming patients as a result of using un-
tested and unproven approaches. More-
over, such approaches may also deprive
the scientific and medical communities
of any data, whether positive or negative,
that might enhance current understand-
ing about these interventions. As the his-
tory of medicine makes clear, adopting
untested interventions without studying
them systematically can be fraught with
peril and should be avoided.
Intellectual Property
It would be a mistake to suggest that the
ethical issues related to intellectual prop-
erty and conflicts of interest are unique
to stem cell research. Nevertheless, be-
cause these conflicts can have profound
effects at every stage of the research
enterprise and the intellectual, financial,
and moral stakes in stem cell research
are so high, they warrant mention. A cen-
tral tension in acknowledging legitimate
intellectual property rights is the potential
effect such acknowledgments can have
on advancing research in general. Obvi-
ously, this involves a balance of reward
for effort and the desire to enhance scien-
tific understanding regarding stem cell
biology. Such questions about intellectual
property may also arise in international532 Cell Stem Cell 2, June 2008 ª2008 Elsecollaboration as well as when working
with commercial entities. The ISSCR
urges negotiation among collaborating
parties regarding these issues so as to
conform to local policies while striving
for maximal availability of materials to
noncommercial entities in the hopes of
advancing science and public benefit
(see ISSCR guidelines).Whether such
recommendations are achievable in all
settings remains unclear, yet explicitly
discussing such issues seems to be an
important first step.
Continuing legal debates about pat-
ented stem cell lines also deserve close
attention (Holden, 2008; Scott, 2008). Of
note, at a more fundamental level, there
is a related debate focusing on the moral
acceptability of patenting human tissue,
which is reflected in different approaches
to patenting across the globe (Plomer
et al., 2008).
Conflicts of Interest
Both nonfinancial and financial conflicts
of interest may adversely affect good
judgment regarding stem cell research.
Although this issue is also not unique to
stem cell science, substantial concerns
have been raised about what could be
considered nonfinancial conflicts of inter-
ests in stem cell research as scientists
rush to publish their findings, sometimes
resulting in error. Indeed, recently an edi-
torial in a high-impact journal went so
far as to suggest that, ‘‘Competition is
good. . .Nonetheless, the fast-moving
fields of science are showing some un-
pleasant tendencies. Researchers are
cutting corners and making mistakes.
They are making over-hyped promises
that will probably be broken.’’ (Editorial,
2008) Although at times difficult to assess
and manage, it is essential that those en-
gaged in stem cell research be alert to the
possibilities of such nonfinancial conflicts
in order to maximize the possibility of
good science and good medicine.
In contrast, financial conflicts of interest
in research may be easier to identify, sim-
ply because financial interests can be
measured and more easily described
than those associated with nonfinancial
interests, such as the advancement of
scientific and professional concerns.
Although having financial interest in
research is understandable, financial
conflicts of interest have the potential to
threaten the integrity of a research effort,vier Inc.and the welfare of research participants,
and so raise serious concerns that must
be managed. Considerable attention has
been directed at these issues in the re-
search enterprise more broadly. Elevated
awareness in this area was instigated in
part by the death of Jesse Gelsinger
during a gene transfer experiment. The
principal investigator and the University
of Pennsylvania, where the research was
conducted, were alleged to have financial
interests dependent on the study out-
come (see reports from the American
Association of Medical Colleges, the
American Association of Universities, and
the United States General Accounting
Office). Current guidelines for stem cell
research touch only briefly on issues of
conflict of interest (Committee on Guide-
lines for Embryonic Stem Cell Research,
National Research Council, 2005; see
also ISSCR guidelines) and thus should
be expanded to accommodate these
important concerns.
Navigating Ethical Issues in Stem
Cell Research
As should be clear, stem cell research and
treatment are immersed in ethical issues
that go far beyond questions that are
related to the destruction of the embryo.
Nevertheless, it is essential that individ-
uals involved in stem cell research and
treatment be alert to these less polarizing
issues so that this incredibly exciting path
of research can be pursued in an ethically
appropriate fashion. Guidelines issued by
the National Academies of Science and
the ISSCR address many of the important
ethical issues in stem cell research (Com-
mittee on Guidelines for Embryonic Stem
Cell Research, National Research Coun-
cil, 2005; Human Embryonic Stem Cell
Research Advisory Committee, National
Research Council, 2007; see also ISSCR
guidelines). Experience using such ap-
proaches is now being garnered, and the
particular approaches taken are rightly
expected to change in step with scientific
progress (Zettler et al., 2007). Although
guidelines and oversight mechanisms
should not be expected to resolve the
full range of ethical issues associated
with stem cell research, they provide a
useful starting point and a process for
sorting through the challenges at hand.
As such, it is incumbent on those engaged
in stem cell research to become familiar
with the available guidelines and to help
Cell Stem Cell
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step with scientific advances in the field.
Overall, it is imperative that guidelines
written to optimize the ethical design
and conduct of stem cell research are
sensitive to the realities of the enterprise
and to its inherent moral concerns.
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